Skip to main content

CPR

Most Viewed

CPR News

.
http://omhthe.com/Kadle-daughter-of-Burich-from-Churriana?Eggenson=232
.
.
.
.

Biohaven: "Rimegepant pivotal phase 3 trial results -- conference call."

Cephalagia: "ARISE: A phase 3 randomized trial of erenumab for episodic migraine."

Kristen Davis, Amgen Media.

David Dodick, MD, neurologist, Mayo Clinic; chairman, American Migraine Foundation.

Harvard Medical School: "CGRP: A New Era for Migraine Treatment."

Jennifer Kay Dial, Eli Lilly Media.

The Journal of Clinical Endocrinology & Metabolism: "Evidence for decreased calcitonin gene-related peptide (CGRP) receptors and compromised responsiveness to CGRP of fetoplacental vessels in preeclamptic pregnancies."

Michelle Larking, Teva Pharmaceuticals Media.

Richard Lipton, MD, director, Montefiore Headache Center; Edwin S. Lowe professor and vice chairman of neurology, Albert Einstein College of Medicine.

Elizabeth Loder, MD, professor of neurology, Harvard Medical School; chief, Division of Headache, Brigham & Women's Hospital.

MarketWatch: "New migraine drugs have promise -- and a ,500 price tag."

Mayo Clinic: "Migraine: Diagnosis & treatment," "Monoclonal antibody drugs for cancer: How they work."

Migraine Research Foundation: "Migraine Facts."

National Headache Foundation: "Facts About Triptans."

Neurotherapeutics: "Targeted CGRP small molecule antagonists for acute migraine therapy."

New England Journal of Medicine: "Fremanezumab for the preventive treatment of chronic migraine."

News release, Alder BioPharmaceuticals Inc.

News release, Allergan.

News release, Amgen.

News release, Biohaven Pharmaceutical Holding Company Ltd.

News release, Eli Lilly.

Stephen Silberstein, MD, director, Jefferson University Headache Center.

News release, FDA.

News release, Amgen.

© 2018 WebMD, LLC. All rights reserved.
.
.
.
.
CPR